Feed

GOVX

GeoVax Labs, Inc.

GOVX · NASDAQ

$0.46 -3.54% (-$0.02)

1M -35.52%

Market Cap $3.43M

P/E Ratio -

Div. Yield -

ROE 743.66%

Piotroski F-Score Weak

2/9

Valuation

89 /100

Cheap

P/B 1.95x

P/E N/A

EV/EBITDA N/A

Growth

78 /100

Growing

Rev. growth 212.55%

Book val. growth 47.61%

EPS growth N/A

Profitability

N/A

Gross margin N/A

Net margin N/A

FCF margin N/A

Quality

0 /100

Poor

ROIC 985.20%

ROE 743.66%

Asset turnover 0.00x

Debt

92 /100

Low

Debt/Equity 0.18x

Current ratio 1.54x

Int. coverage N/A

Stability

1 /100

Unstable

Beta 3.65x

EPS volatility 89.07%

Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about GOVX

Online

About the company

GeoVax Labs (GOVX) is a biotechnology company focused on the development of vaccines for the prevention and treatment of infectious diseases, such as HIV/AIDS, Ebola, Zika virus, and others. Using its patented technological approach, GeoVax develops vaccines aimed at providing effective protection against dangerous pathogens. The company also focuses on vaccine development for emerging threats in public health, including COVID-19. GeoVax Labs (GOVX) shares could be suitable for investors seeking opportunities in the biotechnology sector with a focus on vaccine research and development.

Sector

Healthcare

Industry

Biotechnology

CEO

David Alan Dodd

Employees

Headquarters

Smyrna

Upcoming events

12 NOV

Earnings

Upcoming earnings report

60d

⌘ K

StockBot Live

Market situation Wall Street

Stocks jump as oil prices retreat and inflation meets views

S&P 500 +1.10% and Nasdaq +1.20% rallied to break a losing streak as oil prices eased and inflation met forecasts.

Ask about this

StockBot knows 80,000+ stocks worldwide